SY 161-P5

a polyethylene glycol derivatized (PEGylated) mutant of the recombinant Staphylokinase (rSak) variant SakSTAR, exhibiting reduced antigenicity in clinical development for treatment of acute myocardial infarction as a single bolus injection

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Metalloproteases: 8276
        Metalloendopeptidases: 70
        SY 161-P5: 1
      - Endopeptidases: 633
        Metalloendopeptidases: 70
        SY 161-P5: 1

Experts

1.	Collen, D: 1 article (05/2001)
2.	Moons, L: 1 article (05/2001)
3.	Moreadith, R: 1 article (05/2001)
4.	Rapold, H J: 1 article (05/2001)
5.	Roelants, I: 1 article (05/2001)
6.	Vanlinthout, I: 1 article (05/2001)

Related Diseases

1.	Myocarditis (Carditis) 05/01/2001 - "However, New Zealand white rabbits developed clinically silent, multifocal myocarditis following single or repeat doses of SY 161-P5 or of Sak42D. "
2.	Myocardial Infarction 05/01/2001 - "SY 161-P5, a polyethylene glycol derivatized (PEGylated) mutant of the recombinant Staphylokinase (rSak) variant SakSTAR, exhibiting reduced antigenicity is in clinical development for treatment of acute myocardial infarction as a single bolus injection. "

Related Drugs and Biologics

1.	Polyethylene Glycols (Polyethylene Glycol)
2.	Staphylococcus aureus auR protein (staphylokinase)